Combination therapy for advanced GIST with KIT mutation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—for people with advanced GIST whose tumors have a specific KIT gene mutation (exon 17) and have stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a gastrointestinal stromal tumor (GIST) that has progressed after or you couldn't tolerate standard treatments like imatinib, sunitinib, regorafenib, or ripretinib.
- Genetic testing shows your tumor has a KIT gene mutation in exon 17 (a specific DNA change).
- You have at least one tumor that can be measured on a CT scan or MRI.
- Your blood counts (white cells, platelets, hemoglobin), liver and kidney function, and blood clotting are within certain limits.
- You have not had prior immunotherapy (like a checkpoint inhibitor) and you are able to provide a tumor tissue sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This Phase 2 trial tests whether combining rivoceranib with paclitaxel can shrink or control advanced metastatic gastrointestinal stromal tumor (GIST) after standard medicines have stopped working. It may help people whose GIST has progressed despite prior treatments like imatinib, sunitinib, and regorafenib.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
Hear when a new Metastatic Gastrointestinal Stromal Tumors (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.